IRIS PubliCatt

Scaldaferri, Franco
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 5.855
NA - Nord America 5.686
AS - Asia 2.464
SA - Sud America 59
AF - Africa 46
OC - Oceania 34
Continente sconosciuto - Info sul continente non disponibili 17
Totale 14.161
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.613
DE - Germania 1.387
SE - Svezia 1.262
IT - Italia 1.141
CN - Cina 969
SG - Singapore 695
FR - Francia 367
IE - Irlanda 340
UA - Ucraina 328
PL - Polonia 258
ID - Indonesia 232
GB - Regno Unito 191
FI - Finlandia 170
IN - India 135
RU - Federazione Russa 125
TR - Turchia 112
IR - Iran 107
CA - Canada 55
BE - Belgio 53
KR - Corea 47
NL - Olanda 45
HK - Hong Kong 41
ES - Italia 35
JP - Giappone 34
AU - Australia 29
BR - Brasile 28
CZ - Repubblica Ceca 28
CI - Costa d'Avorio 19
AT - Austria 17
VN - Vietnam 17
EU - Europa 16
CH - Svizzera 15
MX - Messico 15
LT - Lituania 13
RO - Romania 13
TW - Taiwan 13
BG - Bulgaria 12
CL - Cile 12
IQ - Iraq 12
PE - Perù 12
PH - Filippine 10
EG - Egitto 9
IL - Israele 8
PT - Portogallo 8
ZA - Sudafrica 8
HU - Ungheria 6
SI - Slovenia 6
NZ - Nuova Zelanda 5
TH - Thailandia 5
AR - Argentina 4
GR - Grecia 4
HR - Croazia 4
BY - Bielorussia 3
CY - Cipro 3
EE - Estonia 3
KH - Cambogia 3
MK - Macedonia 3
NG - Nigeria 3
NO - Norvegia 3
PK - Pakistan 3
TN - Tunisia 3
AL - Albania 2
BD - Bangladesh 2
BZ - Belize 2
CO - Colombia 2
DK - Danimarca 2
KW - Kuwait 2
LK - Sri Lanka 2
LV - Lettonia 2
MA - Marocco 2
MD - Moldavia 2
RS - Serbia 2
SA - Arabia Saudita 2
UZ - Uzbekistan 2
A1 - Anonimo 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BN - Brunei Darussalam 1
EC - Ecuador 1
GE - Georgia 1
GH - Ghana 1
LI - Liechtenstein 1
LU - Lussemburgo 1
ME - Montenegro 1
MO - Macao, regione amministrativa speciale della Cina 1
NP - Nepal 1
PA - Panama 1
PS - Palestinian Territory 1
QA - Qatar 1
SK - Slovacchia (Repubblica Slovacca) 1
TJ - Tagikistan 1
UG - Uganda 1
Totale 14.161
Salva come PNG Salva come JPEG
Città #
Chandler 1.397
Singapore 561
Ashburn 501
Dublin 335
Jacksonville 239
Jakarta 227
Warsaw 227
San Mateo 202
Rome 185
New York 177
Ann Arbor 167
Wilmington 154
Beijing 148
Nanjing 145
Boston 141
Milan 135
Cattolica 125
Marseille 117
Princeton 115
Fairfield 102
Dearborn 90
Woodbridge 88
Moscow 85
Redwood City 85
Helsinki 82
Houston 76
Seattle 76
Nürnberg 71
Los Angeles 70
Izmir 68
Munich 66
Boardman 62
Lawrence 62
Bremen 58
Hangzhou 56
Nanchang 46
London 45
Brussels 43
Redmond 42
Shanghai 40
Pune 38
Hebei 36
Augusta 34
Mountain View 33
Lancaster 32
Cambridge 31
Chicago 31
Shenyang 31
Tianjin 31
Kunming 29
Changsha 28
Zhengzhou 27
Norwalk 26
Detroit 25
Guangzhou 25
Seoul 25
Washington 25
Frankfurt am Main 23
Kish 22
Paris 22
Trieste 22
Jiaxing 21
Kraków 21
Toronto 21
Fremont 20
Abidjan 19
Falkenstein 19
Andover 17
Leawood 17
Tehran 16
Monza 15
Naples 15
San Diego 14
Vienna 14
Central 13
Brno 12
Hefei 12
University Park 12
Busto Arsizio 11
Hong Kong 11
Jinan 11
Lappeenranta 11
Melbourne 11
Ottawa 11
Tokyo 11
Lanzhou 10
Nuremberg 10
Zurich 10
Berlin 9
Cagliari 9
Falls Church 9
Hanoi 9
Istanbul 9
Stockholm 9
Florence 8
Goyang-si 8
Monmouth Junction 8
San Francisco 8
Santa Clara 8
São Paulo 8
Totale 7.794
Salva come PNG Salva come JPEG
Nome #
The interpaly between immune system and microbiota in gynecological diseases : a narrative review. 524
Gut microbial flora, prebiotics, and probiotics in IBD: their current usage and utility 296
Food Components and Dietary Habits: Keys for a Healthy Gut Microbiota Composition. 206
International consensus conference on stool banking for faecal microbiota transplantation in clinical practice 197
Gut Microbiota Modulation and Mucosal Immunity: Focus on Rifaximin 162
Propionyl-L-carnitine hydrochloride for treatment of mild to moderate colonic inflammatory bowel diseases 158
Anti-TNF-α-induced psoriasiform lesions in IBD: an abnormal immune activation or a 'patchy cutaneous' immune suppression? 155
The role of diet on gut microbiota composition 155
Asthma in patients admitted to emergency department for COVID-19: prevalence and risk of hospitalization 151
Management of acute dyarrhea: current and future trends 147
The gut barrier: new acquisitions and therapeutic approaches 139
Vascular involvement in inflammatory bowel disease: pathogenesis and clinical aspects. 138
Efficacy and Mechanisms of Action of Fecal Microbiota Transplantation in Ulcerative Colitis: Pitfalls and Promises From a First Meta-Analysis 137
Bacterial flora as a cause or treatment of chronic diarrhea 132
Gut Microbiota in Health, Diverticular Disease, Irritable Bowel Syndrome, and Inflammatory Bowel Diseases: Time for Microbial Marker of Gastrointestinal Disorders? 131
13C-octanoic acid breath test to study gastric emptying time 130
Role and mechanisms of action of Escherichia coli nissle 1917 in the maintenance of remission in ulcerative colitis patients: an update 130
Gelatin tannate ameliorates acute colitis in mice by reinforcing mucus layer and modulating gut microbiota composition: Emerging role for 'gut barrier protectors' in IBD? 129
Comparison between clinical and radiological evaluation before and after medical therapy in patients with Crohn's disease: new prospective roles of CT enterography 122
Intercellular adhesion molecule 1 gene polymorphisms in inflammatory bowel disease 120
Nutrition and IBD: Malnutrition and/or Sarcopenia? A Practical Guide 119
Comparison between clinical and radiological evaluation before and after medical therapy in patients with Crohn's disease: new prospective roles of CT enterography 118
Assessment of neurological manifestations in hospitalized patients with COVID-19 117
Locally injected Infliximab ameliorates murine DSS colitis: differences in serum and intestinal levels of drug between healthy and colitic mice 114
Skeletal muscle-gut axis: Emerging mechanisms of sarcopenia for intestinal and extra intestinal diseases 113
Complex Muco-cutaneous Manifestations of CARMIL2-associated Combined Immunodeficiency: A Novel Presentation of Dysfunctional Epithelial Barriers 112
The therapeutic management of gut barrier leaking: the emerging role for mucosal barrier protectors 110
Dietary magnesium: the magic mineral that protects from colon cancer? 106
The Role of Antibiotics in Gut Microbiota Modulation: The Eubiotic Effects of Rifaximin 105
Locally injected Infliximab ameliorates murine DSS colitis: differences in serum and intestinal levels of drug between healthy and colitic mice 104
Validation of an LC-MS/MS Method for Urinary Lactulose and Mannitol Quantification: Results in Patients with Irritable Bowel Syndrome 102
Intestinal gas production and gastrointestinal symptoms: from pathogenesis to clinical implication 97
Mucosal biomarkers in inflammatory bowel disease: key pathogenic players or disease predictors? 96
Acute refractory intestinal pseudo-obstruction in MELAS: efficacy of prucalopride 96
Tricks for interpreting and making a good report on hydrogen and 13C breath tests 94
Therapy experiences and preferences among patients with anemia: Results of a cross-sectional survey among Italian patients with inflammatory bowel disease 94
Tumour necrosis factor-related apoptosis-inducing ligand (trail): a possible pathogenic role in chronic plaque psoriasis 94
Differential CD133 expression pattern during mouse colon tumorigenesis 93
The gastrointestinal microbiome - functional interference between stomach and intestine 93
-Extraintestinal manifestations in inflammatory Bowel disease. 92
Gut microbial flora, prebiotics and probiotics in IBD: their current usage and utility 92
Rifaximin for the treatment of diarrhoea-predominant irritable bowel syndrome 92
European consensus conference on faecal microbiota transplantation in clinical practice 92
RECURRENT PREGNANCY LOSS IS ASSSOCIATED TO LEAKY GUT: A NOVEL PATHOGENIC MODEL OF ENDOMETRIUM INFLAMMATION ? 92
Origin of celiac disease: How old are predisposing haplotypes? 90
Prevention and treatment of venous thromboembolism in patients with IBD: a trail still climbing. 90
Use and indications of cholestyramine and bile acid sequestrants 89
Dysbiosis, gut microbiota modulation and intestinal permeability in recurrent cystitis patients and concomitant gastrointestinal pathologies 89
Use and indications of cholestyramine and bile acid sequestrants 88
Gut microbial flora, prebiotics, and probiotics in IBD: their current usage and utility 88
Pre- and posttherapy assessment of intestinal soluble mediators in IBD: where we stand and future perspectives 88
Pre- and posttherapy assessment of intestinal soluble mediators in IBD: where we stand and future perspectives 88
A novel pathogenic role for microvasculature in inflammatory bowel disease. 86
Sustainability of Endovenous Iron Deficiency Anaemia Treatment: Hospital-Based Health Technology Assessment in IBD Patients 86
Commensal Clostridia: leading players in the maintenance of gut homeostasis 85
A) Platelets: new players in the mucosal scenario of inflammatory bowel disease. 84
Herbal medicinal products for inflammatory bowel disease: A focus on those assessed in double-blind randomised controlled trials 83
Akkermansia muciniphila: key player in metabolic and gastrointestinal disorders 83
Specific 13C functional pathways as diagnostic targets in gastroenterology breath-tests: tricks for a correct interpretation 82
Pancreatic function assessment 78
Body mass index influences infliximab post-infusion levels and correlates with prospective loss of response to the drug in a cohort of inflammatory bowel disease patients under maintenance therapy with Infliximab 77
Small bowel bacterial overgrowth and type 1 diabetes 76
Palaeodiet reconstruction in a woman with probable celiac disease: a stable isotope analysis of bone remains from the archaeological site of Cosa (Italy) 76
Bacillus clausii and gut homeostasis: state of the art and future perspectives 76
Anti-TNF-related leukocytoclastic vasculitis in ulcerative colitis: a case report 76
Clinical, histopathological, and immunological evaluation of a series of patients with erythema nodosum 75
Direct effect of infliximab on intestinal mucosa sustains mucosal healing: Exploring new mechanisms of action 74
Haemostatic system in inflammatory bowel diseases: new players in gut inflammation. 73
Prevention and treatment of venous thromboembolism in patients with IBD: a trail still climbing 73
Gut microbiota and inflammatory bowel disease: an update 72
Multiparametric Evaluation Predicts Different Mid-Term Outcomes in Crohn's Disease 72
Signs of dissociation and symptoms of post-traumatic stress disorder in inflammatory bowel disease. A case-control study 72
Characterization of Sarcopenia in an IBD Population Attending an Italian Gastroenterology Tertiary Center 71
Secretome modulation of Caco-2 cell line induced by a multi-strain probiotic 71
Microbes and Alzheimer' disease: Lessons from H. Pylori and GUT microbiota 71
Mesenchymal Stem Cells Reduce Colitis in Mice via Release of TSG6, Independently of Their Localization to the Intestine 69
Endoscopic ultrasound-guided fine-needle tissue acquisition from a subepithelial lesion in the distal ileum using the forward-viewing echoendoscope 68
Gut Microbiota: A Key Modulator of Intestinal Healing in Inflammatory Bowel Disease 68
Dietary Magnesium Alleviates Experimental Murine Colitis Through Upregulation of the Transient Receptor Potential Melastatin 6 Channel 68
Correction to: Recurrent pregnancy loss is associated to leaky gut: a novel pathogenic model of endometrium inflammation? 67
Microparticles produced by activated platelets carry a potent and functionally active angiogenic signal in subjects with crohn’s disease 66
Tumour necrosis factor-related apoptosis-inducing ligand (trail): a possible pathogenic role in chronic plaque psoriasis 65
The current practice of lynch syndrome diagnosis and management in Italy: A qualitative assessment 65
Comparison of performances of infliximab biosimilars CT-P13 versus SB2 in the treatment of inflammatory bowel diseases: a real-life multicenter, observational study in Italy 65
Exploring Bacteroidetes: Metabolic key points and immunological tricks of our gut commensals 64
Cancer and Mediterranean Diet: A Review 63
Molecular signaling blockade as a new approach to inhibit leukocyte-endothelial interactions for inflammatory bowel disease treatment. 62
Enterography CT without and with water enema in patients with Crohn's disease: Results from a comparative observational study in comparison with endoscopy 62
Intestinal permeability in physiological and pathological conditions: major determinants and assessment modalities 62
Long-term evaluation of quality of life and gastrointestinal well-being after segmental colo-rectal resection for deep infiltrating endometriosis (ENDO-RESECT QoL) 62
Acute refractory intestinal pseudo-obstruction in melas: Efficacy of prucalopride 61
Crohn's disease activity before and after medical therapy evaluated by MaRIA score and others parameters in MR Enterography. 61
Tumor necrosis factor-α and solute carrier family 22 member 4 gene polymorphisms as potential determinants of intestinal dysbiosis 61
Combination therapy in inflammatory bowel disease – from traditional immunosuppressors towards the new paradigm of dual targeted therapy 61
Can we predict the efficacy of anti-TNF-α agents? 60
Impact of the Trophic Effects of the Secretome From a Multistrain Probiotic Preparation on the Intestinal Epithelia 59
Knowledge of Diagnostic and Therapeutic Aspects of IBD Among Nurses Working in Digestive Endoscopy: A Nationwide Italian Survey 59
One-year effectiveness and safety of ustekinumab in ulcerative colitis: a multicenter real-world study from Italy 59
Usefulness of contrast-enhanced ultrasound (CEUS) in Inflammatory Bowel Disease (IBD) 58
Drug-Related Pneumonitis in Patients Receiving Vedolizumab Therapy for Inflammatory Bowel Disease 58
Totale 9.951
Salva come PNG Salva come JPEG
Categoria #
all - tutte 70.981
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 70.981
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020708 0 0 0 0 0 0 158 72 121 86 173 98
2020/20211.193 58 141 20 116 176 89 133 24 126 75 202 33
2021/20221.744 120 83 37 101 123 57 26 241 86 190 345 335
2022/20233.959 513 511 297 601 238 467 195 343 455 80 161 98
2023/20242.401 105 537 99 153 100 317 186 94 127 135 264 284
2024/20251.481 103 152 431 155 431 200 9 0 0 0 0 0
Totale 14.444